Results 201 to 210 of about 10,858,974 (235)

Talimogene Laherparepvec (T-VEC)

open access: yes, 2021
Talimogene laherparepvec (T-VEC, IMLYGIC®) is the first approved oncolytic virotherapy for the treatment of patients with advanced melanoma. As the drug is administered intratumorally, it is mainly suitable for the treatment of (sub)cutaneous lesions.
Zdzienicki, Marcin   +3 more
openaire   +2 more sources

Is There Still a Role for Talimogene Laherparepvec (T-VEC) in Advanced Melanoma? An Indirect Efficacy Comparison of T-VEC Plus Ipilimumab Combination Therapy Versus T-VEC Alone as Salvage Therapy in Unresectable Metastatic Melanoma

Expert Opinion on Biological Therapy, 2021
Talimogene laherparepvec (T-VEC) improves overall survival (OS) in unresectable stage IIIB/C-IV melanoma T-VEC may have synergistic effects with CTLA-4 inhibitors In the absence of a trial comparing T-VEC and ipilimumab (T-VEC + IPI) to T-VEC, we applied a novel indirect comparison method using extrapolated OS curves to estimate OS outcomes in a ...
Ahmad Alamer   +2 more
exaly   +3 more sources

The Transformation Matrices of Vec a to Vec A^T for Diagonal Matrix [PDF]

open access: yesInternational Journal of Progressive Sciences and Technologies, 2023
This study aims to discusses the transformation matrices of vec A to vec A^T for diagonal matrix. The matrix used is a 4 x 4 diagonal matrix assuming that two pairs of elements are located on the main diagonal with the same value.
Yulianti, Lyra   +2 more
exaly   +2 more sources

T-VEC Oncolytic Viral Therapy Shows Promise in Melanoma

Nature Reviews Clinical Oncology, 2015
David Killock
exaly   +2 more sources

Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective

Journal of Immunotherapy, 2022
Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus type 1, which can be administered intralesionally in patients with stage IIIB/C-IVM1a (American Joint Committee of Cancer; AJCC 7th edition) unresectable melanoma.
Viola, Franke   +6 more
openaire   +2 more sources

Talimogene laherparepvec (T-VEC) as cancer immunotherapy

Drugs of Today, 2015
Talimogene laherparepvec (T-VEC) is the first-in-class oncolytic virus immunotherapy for the treatment of cancer and was generated from an attenuated, recombinant herpes simplex virus. T-VEC has demonstrated therapeutic activity in melanoma patients and is being tested in a number of other cancers alone and in combination with standard cancer ...
F J, Kohlhapp, A, Zloza, H L, Kaufman
openaire   +2 more sources

Oncolytic Viruses: T-VEC and Others

2017
Immunotherapy has become a standard for treatment of several advanced cancers such as melanoma, lung cancer, and head and neck cancer. Lymphocyte-rich tumor microenvironment is a predictor factor for response to immunotherapy. Although, theoretically, these tumor-infiltrating lymphocytes should be highly immunogenic, it has been shown that the tumor ...
Rutika Mehta, Igor Puzanov
openaire   +1 more source

Home - About - Disclaimer - Privacy